← Eichor
Study identifier: NCT07704632 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Safety and Feasibility of FUS Next Generation Dome Helmet (NGDH) to Perform Neuromodulation in Patients With Treatment Refractory Obsessive Compulsive Disorder (OCD)

Condition: OCD · Obsessive-Compulsive Disorder (OCD) · Obsessive-Compulsive Disorder  ·  Sponsor: Sunnybrook Health Sciences Centre

PhaseNA
Planned participants20
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

This study evaluates the safety, feasibility, and preliminary efficacy of focused ultrasound (FUS) neuromodulation delivered using the Next Generation Dome Helmet (NGDH) in participants with treatment-refractory obsessive-compulsive disorder (OCD). Participants will undergo two study sessions, four weeks apart, involving active FUS neuromodulation targeting nodes of the cortico-striato-thalamo-cortical (CTSC) circuit. Outcomes include adverse events, changes in OCD symptom severity, and quality of life.

This description comes directly from the study's public registry record.

Talk to the study team

Nir Lipsman, MD, PHD, FRCSC, FAANS  ·  (416)-480-6954  ·  Nir.Lipsman@sunnybrook.ca

Anusha Baskaran, PhD  ·  416-480-6100  ·  anusha.baskaran@sunnybrook.ca

Always discuss trial participation with your own doctor first.

Locations (1)

Sunnybrook Health Sciences CentreToronto, Ontario, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07704632